14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CELU vs GPCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GPCR Captures Overall Composite Edge (40.9 SELL vs 42.9 HOLD), While CELU Leads 3–2 on Growth & Valuation Pillars
GPCR Overall Winner
6-Pillar Tally: CELU 3 – 2 GPCR (1 Tie)
Matrix Metrics: CELU 2 – 6 GPCR
As of Nov 20, 2026, Structure Therapeutics Inc. (GPCR) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (40.9/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. CELU trades at $0.46 (N/M Forward P/E, -254.0% operating margin) versus GPCR at $16.13 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While CELU currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. GPCR 40.9/100 SELL), GPCR captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.0% operating margin) and revenue trajectory (+0.0% vs. -5.3% YoY).
Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile GPCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELU vs GPCR. Trailing 12-month operating profitability (CELU -254.0% vs GPCR 0.0%) and valuation multiples (CELU N/M vs GPCR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CELU vs GPCR Key Questions & Quantitative Answers
As of Nov 20, 2026, Structure Therapeutics Inc. (GPCR) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (40.9/100 SELL vs. 42.9/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Profitability & Quality), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. CELU trades at $0.46 (N/M Forward P/E, -254.0% operating margin) versus GPCR at $16.13 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CELU currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. GPCR 40.9/100 SELL), GPCR captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -254.0% operating margin) and revenue trajectory (+0.0% vs. -5.3% YoY). Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile GPCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GPCR leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with GPCR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CELU generates $19M in USD-normalized revenue versus N/A for GPCR. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GPCR.
CELU screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas GPCR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus GPCR (-29.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, GPCR carries 120.4% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.31β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.